Labiotech.eu

News and Trends 26 Jul 2017

Update: Potential Breakthrough Treatment for Deadly Lung Disease Starts Phase IIb

Update (26/07/2017): Verona Pharma has dosed the first patients in the PhaseIIb with RPL554 in patients with chronic obstructive pulmonary disease (COPD). Results are expected in the second half of 2018. Published on 27/06/2017 Verona Pharma has secured regulatory approval in five European countries to run a Phase IIb trial with its dual PDE3/4 inhibitor in […]

July 26, 2017 - 2 minutesmins - By Melanie De Almeida

In Depth 25 Jul 2017

Trouble in Paradise: How Biotech is Fighting Tropical Diseases

Tropical diseases are often neglected until an outbreak causes worldwide panic. Here’s how European biotech is preparing for the next one. “What we really need is a very fast and cheap way to develop vaccines,” biotech godfather Greg Winter told me earlier this year. Such precautionary measures may well be on our minds as Europe […]

July 25, 2017 - 6 minutesmins - By Evelyn Warner

More News! 24 Jul 2017

Bayer and Evotec Extend their Endometriosis Partnership

Bayer and Evotec have decided to extend their partnership for the development of endometriosis drugs now that their second candidate has made it to Phase I. Bayer and Evotec have announced today that a second compound derived from their endometriosis partnership has made it to clinical trials. The team has decided to extend the partnership […]

July 24, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 24 Jul 2017

How can Recombinant Proteins be used in Veterinary Medicine?

This expert has told us why recombinant proteins are an elegant way to go in the production of veterinary vaccines and why glycosylation patterns can play a big part in all of it! For many decades, human blood plasma has been a source of different biotherapeutic proteins, including antibodies, albumin and blood coagulation factors. Although they are […]

July 24, 2017 - 5 minutesmins - By External Contributor

Francis Crick institute Veronique Birault Head of Translation

Interview 24 Jul 2017

Discussing Open Science with the Head of Translation at The Francis Crick Institute

Officially opened less than a year ago, The Francis Crick Institute is already conducting top-level biomedical research, has launched two spin-outs and struck research partnerships with both AstraZeneca and GlaxoSmithKline. I spoke to the Head of Translation, Dr. Véronique Birault, to learn more about the Crick’s unique model of translation and the key for its […]

July 24, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Jul 2017

Roche Abandons Spanish Cancer Epigenetics Drug

Roche has decided to terminate its license agreement with Spanish biotech Oryzon Genomics after rearranging its portfolio priorities. Oryzon Genomics, a biotech based in Barcelona working on epigenetics, was notified yesterday by Roche about the discontinuation of their deal concerning the biotech’s lead candidate, ORY-1001. Roche announced the decision was not based on clinical data, […]

July 21, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 20 Jul 2017

Update: Danish Psoriasis Drug Gets EU Approval Despite Suicide Links

Update (20/07/2017): The European Commision has granted LEO Pharma marketing authorization for Kyntheum (brodalumab), making it the first biologic drug that targets IL-17a. Published 22/05/2017 The EMA has taken up a positive opinion for Leo Pharma’s psoriasis drug brodalumab, even though the drug has been associated with suicidal behavior. Brodalumab, a fully human antibody targeting the […]

July 20, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 20 Jul 2017

Sanofi Offers up to €2.4Bn to Belgian Biotech to Develop Nanobodies

Ablynx and Sanofi have entered a research collaboration and exclusive licensing agreement for up to eight nanobody candidates for immune and inflammatory disease. Ablynx, based in Belgium, develops nanobodies, single-domain antibodies inspired on those of camels and llamas that have the advantage of being much smaller than standard antibodies. This technology has caught the attention of Sanofi, […]

July 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Interview 20 Jul 2017

Video – DNA Molecular Combing for the Early Detection of Genetic Diseases

It’s been more than a month since Refresh, but the topic of our last expert track is as current as ever: DNA analysis for the early detection of genetic diseases. Charles Caulliez, Director of Corporate Business Development at Genomic Vision, started his talk by introducing the company: In 2004, Aaron Bensimon (CEO) founded Genomic Vision as […]

July 20, 2017 - 3 minutesmins - By External Contributor

SHIVA Trial Precision Medicine Cancer France

In Depth 20 Jul 2017

SHIVA Trial: France’s Big Shot at Precision Medicine for Cancer

SHIVA01 and SHIVA02 are large-scale trials run in France to evaluate the efficacy of precision medicine that have created ripples in the oncology field. Although molecular alterations are shared among different types of cancer, drug development today is still mainly based on tumor localization. The only recent exception is MSD’s Keytruda (pembrolizumab) an antibody approved by […]

July 20, 2017 - 5 minutesmins - By Timothé Cynober

News and Trends 19 Jul 2017

FREE White Paper! All You need to Know about Omics and Body Fat

What do you think when you hear the word ‘lipid’? I bet your thoughts include fat, energy, hormones, maybe cells? But what if I told you that lipids can also be considered as biomarkers? Very important biomarkers too that can be analyzed and identified using multiparametric statistical analysis! With more and more research focusing on […]

July 19, 2017 - 3 minutesmins - By External Contributor

Tiziana Life Sciences HCC milciclib cancer

News and Trends 19 Jul 2017

Update: British Biotech Starts Phase II Trial in the Second Deadliest Cancer

Update (19/07/2017): Tiziana has enrolled its first patient with refractory hepatocellular carcinoma in the Phase IIa trial with milciblib. Results are expected in the fourth quarter of 2018. Published on 24/04/2017 Tiziana Life Sciences has received approval to start Phase II in Israel with its leading compound, a CDK inhibitor targeting one of the deadliest cancers. […]

July 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us